Bridgefront Capital’s Verastem VSTM Stock Holding History

Bridgefront Capital’s Portfolio VSTM Stock Details VSTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,500	Closed	-$73K	–	681
2021 Q2	$73K	Buy	+1,500	New	+$62.5K	0.03%	566

Other funds holding VSTM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Bridgefront Capital's VSTM Position: Q3 2021 in Review

Bridgefront Capital sold out of Verastem (VSTM) in Q3 2021, closing a stake of 1,500 shares — an estimated $73K sold.

Bridgefront Capital first reported a position in VSTM in Q2 2021 and held it in 1 quarter. The position peaked at $73K in Q2 2021. 147 funds tracked by Wall St. Rank hold VSTM as of Q3 2021.

Bridgefront Capital reported no remaining Verastem position as of Q3 2021 after selling out during the quarter.
Bridgefront Capital sold 1,500 Verastem shares in Q3 2021, an estimated $73K.
Bridgefront Capital first reported a position in Verastem in Q2 2021 and held it in 1 quarter.
Bridgefront Capital's Verastem position peaked at $73K in Q2 2021.
147 funds tracked by Wall St. Rank held Verastem as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.